Sleep disorders are highly prevalent among individuals with multiple sclerosis (MS), affecting nearly half of the patient population, according to study results presented at the European Committee for ...

A machine learning–based tool accurately predicted risk for recurrent inflammatory activity after DMT discontinuation in MS, highlighting its potential to guide personalized treatment decisions.

Patients with primary progressive MS more commonly exhibited delays in overall disability progression following treatment with ocrelizumab vs placebo.

Almost half of women with MS remain untreated during family planning, though ocrelizumab is the most commonly used DMT in this population.

The majority of infections in multiple sclerosis (MS) are reported in non-neurology practices, according to study results presented at the European Committee for Treatment and Research in Multiple ...